Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.45 |
| ▸ | HTR3B | O95264 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 3/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859026 | 0.86 | CHRNA7 (0.49) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7062084 | 0.82 | CHRNA7 (0.68) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7061250 | 0.82 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7654015 | 0.82 | FPR2 (0.38) | — | |
| SCHEMBL7062789 | 0.78 | ALDH1A1 (0.53) | CHRNA7HTR3A | |
| SCHEMBL7124295 | 0.78 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5072917 | 0.76 | CHRNA7 (0.64) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5075991 | 0.74 | CHRNA7 (0.53) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7125092 | 0.73 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6881030 | 0.72 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | CHRNA7 304/4885HTR3E 1023/4885HTR3B 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.